SNF_TzExVivoGran - Human in vitro granulomas to dissect tuberculosis protective immune traits and assess drug candidates for tailored adjunct host-directed therapy

Taking advantage of a unique collection of human clinical specimens and our established in vitro granuloma model, we aim to gain important knowledge on some of the intrinsic differential immune traits that defines a protective response against MTB. We will demonstrate that in vitro granulomas constitute a relevant tool to study drug-targetable host immune pathways linked to clinical TB severity in a given epidemiological setting. These results will have an impact on the design and selection of host-directed therapy agents against TB. In addition, we will demonstrate that such interventions may require considering immune specificities at the individual level.

Contact

Damien Portevin

Damien Portevin, PD, PhD
Scientist, Scientific Group Leader

+41612848149
damien.portevinswisstph.ch

Project Facts